Business
NeuroOne Medical Technologies Corporation Appoints Ronald McClurg, Experienced Financial Industry Executive, as Chief Financial Officer
EDEN PRAIRIE, Minn., Jan. 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on
About this update from Neuroone Medical Technologies Corporation
[{"type":"text","content":"EDEN PRAIRIE, Minn., Jan. 7, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Ronald McClurg, an experienced senior financial industry executive, as Chief Financial Officer of NeuroOne Medical Technologies Corporation. Mr. McClurg has over 30 years of financial leadership experience with both public and privately held companies. He has held the role of CFO for a number of public companies including Orthomet, Inc., Video Sentry Corporation, and Insignia Systems, Inc. He also held the role of CFO at Incisive Surgical, a privately held medical device company. He began his career in public accounting with Ernst and Young, where he earned his CPA certificate. \n\n \n \n \n \n \n \n\n \nDave Rosa, President and CEO of NeuroOne, says, \"Over the past quarter the Company has made great progress in achieving key milestones and building our infrastructure. With our future goal to uplist to a major national securities exchange, it became critical to add a seasoned senior financial executive such as Ron. His broad experience with both public and private companies as well as his familiarity with medical device companies make him an ideal fit for the role of CFO at NeuroOne. We are very fortunate to have him as part of the NeuroOne family and look forward to working with him.\"\nMr. McClurg states, \"I'm excited to join the NeuroOne team because I believe in the Company's growth strategy to improve outcomes for patients suffering from neurological disorders and enhance shareholder value. I feel that my skills and experience will complement those of the rest of the NeuroOne leadership team.\"\nNeuroOne received FDA clearance for its Evo™ cortical electrode technology in November 2019. It plans to submit a second 510(k) application for its sEEG electrode technology in the first half of 2021 to bolster its product portfolio for use in recording, monitoring and stimulating brain tissue for up to 30 days. In addition, the Company continues developing therapeutic electrodes for use in Parkinson's Disease, epilepsy and back pain due to failed back surgery.\nIn partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other...